The IPAB platform regularly deals with therapeutic antibodies and in this context benefits from two advantages:

• IRCM Integration, numerous collaborations with biotechnology companies in Montpellier and proximity to the University Hospital of Montpellier.
• Biomolecules with high-performance human and material resources.